What Albutein Treats: Main Uses and Benefits

Albutein is commonly used to help with symptoms related to systemic imbalance, such as low circulating blood volume and hypoalbuminemia, which may present with fluid imbalances and swelling.

Supporting Circulating Volume in Acute Situations

Albutein is generally used in clinical settings that involve acute or unstable symptom patterns to address the consequences of rapid and significant volume loss, which typically presents as dangerous low blood pressure (hypotension) and signs of circulatory collapse. It provides supportive relief that assists with maintaining functional stability when symptoms of acute episodes, such as shock or major fluid loss, become disruptive.

Managing Fluid Imbalance and Severe Protein Deficiency

The medication is applied to address symptom clusters that may become intense or disruptive in patients suffering from severe hypoalbuminemia (critically low protein levels), a condition that often leads to generalized tissue swelling (edema). This supportive action assists the body in regulating fluid balance, which helps ease the overall symptom burden associated with fluid misdistribution.

Specialized Clinical Support

The medicine is applied in specific contexts involving episodic or fluctuating manifestations, such as assisting with fluid stability during complex procedures like cardiopulmonary bypass surgery. It is also used to help manage hyperbilirubinemia (severe jaundice) in vulnerable infants, providing supportive relief when symptoms interfere with daily comfort.

---

Quick Fact: Relief for Low Circulating Volume

Albutein is commonly used to help maintain adequate circulating blood volume when acute symptoms interfere with functional stability, providing essential support in emergency fluid management scenarios.

Who Can and Cannot Use Albutein (Human Albumin)

Albutein's eligibility is strictly defined by regulatory documents, focusing on patient safety based on pre-existing conditions and known risks.

---

Contraindications (Must Not Use)

Individuals must not use Albutein if they have:

• Hypersensitivity (allergy) to human albumin preparations or any ingredient in the formulation.
• Severe anemia.
• Cardiac failure (heart failure) when accompanied by a normal or increased volume of blood (intravascular volume).

---

Restricted or Conditional Use (Use with Caution)

Caution is required in patients where volume expansion or blood dilution (hemodilution) poses a special risk. These conditions include:

• Decompensated heart failure.
• Hypertension.
• Pulmonary edema (fluid in the lungs).
• Esophageal varices.
• Renal or post-renal anuria.

---

Special Populations and Eligibility

Population Group	Eligibility Status
Pregnancy	Safety not established in controlled trials; use only if clearly needed.
Lactation	Safety not established in controlled trials; use only if clearly needed.
Neonates (Newborns)	Established use for hyperbilirubinemia.
General Pediatrics	Safety and efficacy not established in controlled clinical trials for all presentations.

Interactions with other medicines and products

Albutein (Albumin Human) possesses an officially documented interaction profile that is highly restricted, reflecting its composition as a natural, plasma-derived protein. Unlike synthetic small-molecule drugs, Albumin Human is not metabolized through the hepatic Cytochrome P450 (CYP) enzyme system, and regulatory prescribing information does not list any corresponding pharmacokinetic drug-drug interactions. Consequently, official government documents do not cite transporter-based interactions (P-gp, OATP) or mandatory administration timing rules that require doses of other medicines to be separated by a specific duration.

The primary interaction constraint documented in official government sources involves a pharmacodynamic effect. The concurrent use of Albumin Human with Angiotensin-Converting Enzyme (ACE) Inhibitors (a class of blood pressure medicines) has a specific, heightened risk when administered during therapeutic plasma exchange procedures. Under these constrained conditions, the combination is officially associated with the regulatory outcome of marked hypotension (severe low blood pressure). This restriction focuses on a narrow patient context where the potential for additive effects on blood pressure is amplified. Furthermore, official documentation states that no interactions are documented for Albutein with food, alcohol, supplements, or herbal products.

Albutein is a formulation of human albumin, a large, single-chain globular protein that distributes predominantly throughout the extracellular space, with approximately 30–40% remaining in the intravascular compartment. Its primary mechanism of action is mediated by its substantial colloid osmotic pressure effect, which is attributed to its molecular size and negative charge.

In the systemic circulation, its presence generates an osmotic gradient across the capillary membrane. This gradient facilitates the movement of water from the interstitial space into the intravascular space, a process that increases the circulating plasma volume. This volume expansion leads to a systemic physiological consequence of elevated intravascular volume and decreased blood viscosity.

Secondary actions involve its function as a non-specific carrier protein, binding a wide array of endogenous ligands, including fatty acids, hormones, bilirubin, and transition metal ions, as well as exogenous substances. It also exhibits an antioxidant action through the scavenging of reactive oxygen species. Furthermore, it interacts with the neonatal Fc receptor (FcRn) on endothelial cells, which mediates its prolonged plasma half-life through a pH-dependent endosomal recycling pathway.

Official Administration Guidelines for Albutein

Albutein (Albumin Human) is a solution for infusion that must be administered only via the intravenous (IV) route. Dosage and infusion rate are highly individualized based on the patient's condition and the adequacy of circulating blood volume, not solely on serum albumin levels. The total daily dose must not exceed 2 grams per kilogram (2 g/kg) of body weight.

---

Dosing Rules and Schedules

Patient Group & Condition	Standard Labeled Dose & Adjustment	Frequency & Timing
Adult Hypovolemia	Initial dose: 20 g to 25 g albumin.	Additional dose may be given if response is inadequate within 15 to 30 minutes.
Adult Hypoalbuminemia	Range: 50 g to 75 g albumin.	Infusion rate is adjusted to patient’s needs.
Pediatric Use	Hypovolemia: 0.5 to 1 g/kg body weight.	Additional dose may be given within 15–30 minutes if needed.

---

Preparation and Administration Requirements

Preparation:

• The solution must be visually inspected before use for any discoloration or particulate matter; do not use if turbid.
• Albutein must not be diluted with Sterile Water for Injection as this can cause hemolysis in the recipient. Approved diluents are 0.9% saline or 5% dextrose.
• If administering large volumes (e.g., over 1,500 mL), the product should be warmed to room temperature before infusion.

Infusion Rate & Timing:

• The infusion must begin within four hours of piercing the vial stopper, as the solution contains no preservative; any unused portion must be discarded.
• For the concentrated 25% solution, doses over 100 mL should not be infused faster than 100 mL in 30 to 45 minutes to help avoid circulatory compromise.

Albutein: Recent Clinical Evidence

Evidence for Volume Restoration in Acute Circulatory Situations

Research, primarily using Randomized Controlled Trials (RCTs), has studied for outcomes related to systemic imbalance in acute situations like shock or low circulating blood volume. Researchers monitored blood pressure and fluid metrics, along with overall patient survival. Studies reported immediate changes in volume metrics following administration. However, findings related to overall long-term survival varied across the major trials. Evidence across diverse groups of critically ill patients is often heterogeneous, and certainty remains low for broad conclusions.

Evidence for Managing Complications of Advanced Liver Disease

Albutein was studied for its role in managing complications during large-volume paracentesis (fluid removal) for patients with liver cirrhosis. The studies monitored the PICD biomarker (a measure of circulatory changes) and the incidence of kidney impairment. Evidence contributes to understanding short-term symptom patterns following this procedure, but the data for long-term effects are not fully established.

Evidence for Severe Protein Deficiency (Hypoalbuminemia)

RCTs and observational studies examined outcomes related to systemic or functional imbalance in patients with severely low protein levels caused by acute conditions like severe burns or sepsis. Trials monitored changes in the serum albumin biomarker and related metrics like tissue swelling (edema). The findings were highly dependent on the patient’s specific underlying disease, and evidence for chronic low protein levels is limited.

Evidence in Specialized or Specific Clinical Sub-Populations

Research has examined the use of Albutein in distinct groups, including adult patients undergoing cardiac surgery (where postoperative fluid needs were monitored) and vulnerable infants with severe jaundice. For infants, studies monitored measurements of the free bilirubin biomarker and the incidence of exchange transfusion. In these specialized areas, sample sizes were modest, and follow-up durations were limited.

What Remains Unclear or Inconsistent in the Research

Across all indications, a common feature is that follow-up durations were limited, focusing on the immediate acute period. The long-term impact on survival or sustained durability is not fully established. Overall, findings related to survival were mixed, and comparative evidence is lacking in certain areas, indicating that the certainty remains low where research is ongoing.

Key Studies & References

1. Comparison of the effects of albumin and crystalloid on mortality among patients with septic shock: systematic review with meta-analysis
2. Intravenous albumin in cirrhosis: Updated clinical uses and novel perspectives

Common questions about Albutein (FAQ)

Q: Is Albutein used for anything other than treating low albumin levels?

According to the official product information, Albutein is used to manage several acute conditions besides low albumin. Regulatory documents describe its role in addressing severe fluid loss (hypovolemia), shock, burns, and to prevent complications following the removal of large volumes of fluid due to liver cirrhosis (paracentesis).

Q: How quickly should I expect to see effects after receiving an Albutein infusion?

Albutein is used to support rapid volume restoration. The official administration guidelines suggest that a patient's response is typically monitored and observed within 15 to 30 minutes after the infusion begins to see if the treatment is achieving the intended goal.

Q: How long does the therapeutic effect of Albutein typically last in the body?

The protein component of the medicine is reported to have a plasma half-life—the time it takes for half the substance to be eliminated—of approximately 15 to 20 days in healthy adults. This figure indicates how long the protein remains present in the blood circulation.

Q: What are the most commonly reported side effects of Albutein?

Adverse reactions reported in official documents include reactions such as flushing, hives (urticaria), fever, nausea, and chills. Severe allergic reactions, such as anaphylactic-type reactions, are also reported in the product information.

Q: Is Albutein used differently for children compared to adults?

Official prescribing information provides specific administration information for children and infants that differs from that for adults. Furthermore, Albutein has an established and distinct use for managing severe jaundice (hemolytic disease) in newborns, which is a different purpose than adult volume expansion.

Q: What is the difference between Albutein and other albumin solutions?

Albumin Human solutions are manufactured in different concentrations, typically 5% (less concentrated) and 25% (more concentrated). According to official documents, the concentrated 25% solution is indicated in medical situations where fluid intake must be strictly controlled, such as when aiming to shift fluid from the tissues back into the circulation.

Q: Can Albutein be mixed with other medications in the same intravenous line?

Regulatory documents state that Albutein should not be mixed with certain substances to prevent the protein from becoming unstable or precipitating (clumping). Mixing with protein hydrolysates, amino acid mixtures, or solutions that contain alcohol is cautioned against in regulatory documents.

Q: Why do patients with burns often receive Albutein?

Albumin is officially indicated in patients with severe burn injuries to address protein loss and support circulatory stability after the initial phase of injury. Its use is described to support fluid management needs.

Q: What does 'contraindication' mean in the context of Albutein use?

A contraindication is a medical term for a condition or circumstance that makes the use of a medicine potentially harmful. When a drug is contraindicated, it means that the medicine is not recommended for use under those specific, officially listed circumstances.

Q: Can people with certain allergies still receive Albutein?

The medicine is strictly contraindicated only in patients who have a known hypersensitivity (allergy) to albumin preparations or to any of the ingredients used in the product’s formulation. Allergies not related to the product are not listed as contraindications.

Q: Can people with pre-existing kidney conditions be treated with Albutein?

Official information states that caution should be exercised in individuals with certain kidney conditions, such as anuria, or when there is a risk of circulatory overload. However, the medicine is also indicated for other kidney-related issues like acute nephrosis.

Q: What should I do if I think I am experiencing a side effect from Albutein?

Official guidance indicates that if an adverse reaction occurs, the infusion should be slowed or stopped, and individuals should seek guidance from the professional administering the medicine.

Q: Is Albutein used to treat conditions involving fluid retention or swelling?

Studies and official information support its use in conditions where fluid moves into the body tissues, causing swelling (edema). For example, it is used in acute nephrosis and in severe burns to support the management of systemic swelling.

Q: Are there any official warnings about driving or operating machinery after receiving Albutein?

Official regulatory documents specifically state that Albutein has no known influence, or only a negligible influence, on an individual’s ability to drive and use machines.

Q: Is Albutein known to affect the results of any common laboratory tests?

Official documents contain information that indicates that if large volumes or high doses are administered, the resulting increase in circulating fluid volume can potentially affect the reliability and values of certain common laboratory test parameters.

How to Store and Dispose of Albutein

Albutein (Albumin Human) must be stored according to specific regulatory requirements to maintain the solution's stability and integrity. The product must be stored at temperatures not exceeding 30 C (86 F) and must not be frozen. It should also be kept in the original container to protect from light.

Stability and Handling

As Albutein contains no preservatives, it is supplied as a single-use product. The administration of the solution must begin within four hours after the container has been entered (pierced). Before use, the solution must be visually inspected for discoloration or particulate matter, and must not be used if the seal is broken or the product is turbid.

Disposal Instructions

Any portion of the product remaining unused after the four-hour limit must be discarded. Disposal of unused medicine or waste material must be carried out in accordance with local regulatory requirements.